Skip to content
MMJ Gazette
  Sunday 1 February 2026
  • About
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Authors
  • Home
  • News
  • CBD
  • Cannabis
  • Drugs
  • Marijuana
  • Tobacco
  • Law
Trending
January 31, 2026Colorado THC Vapes Flooded with Converted Hemp, Experts Sound Alarm January 29, 2026California Smashes Own Record: $609 Million in Illegal Cannabis Destroyed January 28, 2026Trump Allies Push to Kill Arizona Adult-Use Marijuana Sales January 18, 2026Florida’s Marijuana Legalization Battle Hits New Lows in 2026 January 16, 2026Montana Cannabis Sales Smash Records with $327 Million Haul January 15, 2026Cannabis M&A Surge Sparks Hope After Trump Order January 14, 2026Massachusetts Cannabis Ban Hit by Fraud Claims in 2026 Vote January 13, 2026Texas Medical Cannabis Set to Explode in 2026 January 10, 2026Cannabis Firms Face HR Compliance Crunch in 2026 January 9, 2026Oregon Cannabis Sales Drop in 2025 Despite Record Harvests
MMJ Gazette
MMJ Gazette
  • About
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Authors
MMJ Gazette
  Cannabis  High Tide Reconsiders Acquisition of German Cannabis Operator Purecan
CannabisMarijuanaNews

High Tide Reconsiders Acquisition of German Cannabis Operator Purecan

Lars BeckersLars Beckers—February 26, 20250
FacebookTwitterPinterestLinkedInTumblrRedditVKWhatsAppEmail

High Tide, a major player in Canada’s cannabis retail industry, is pulling back on its planned acquisition of German medical marijuana operator Purecan GmbH. The Calgary-based company initially set out to acquire a 51% stake in Purecan for €4.8 million ($4.9 million), but after reviewing the details, it’s now reevaluating how—or if—it wants to proceed.

A Tuesday news release confirmed that while High Tide is still considering alternative ways to work with Purecan, there’s no certainty that a deal will happen.

Why High Tide Is Having Second Thoughts

The original deal, announced on January 13, was meant to give High Tide a foothold in Germany’s growing cannabis market. Purecan, a Frankfurt-based importer, already has key assets that made it an attractive target, including:

  • A European wholesale and import license.
  • Warehousing and logistics capabilities.
  • A telemedicine platform to connect with patients.

Despite these advantages, High Tide’s due diligence process led to hesitation. The company has not publicly disclosed specific concerns, but this kind of pause often signals financial, regulatory, or operational risks that weren’t initially apparent.

One thing is clear: High Tide isn’t ready to fully walk away. The company is keeping the door open for a restructured deal while also exploring other options to break into Germany’s cannabis market.

Germany’s Cannabis Market Is Shifting Fast

Germany is already one of the world’s biggest cannabis importers, with nearly half of its supply coming from Canada. Last April, the country made a major shift by removing marijuana from its narcotics list and legalizing limited adult-use sales. This created fresh business opportunities for both local and international cannabis companies.

But political uncertainty could complicate things. Conservative leader Friedrich Merz recently won the German elections, and his party has been vocal about its opposition to cannabis legalization. This could mean new restrictions or even a rollback of recent reforms, making the landscape more unpredictable for companies like High Tide.

What’s Next for High Tide?

High Tide isn’t giving up on Germany. Even if a deal with Purecan falls through, the company has made it clear that it’s actively seeking other ways to enter the market.

For now, its options could include:

  • Partnering with a different German operator to avoid the risks associated with Purecan.
  • Expanding its wholesale business in Europe without relying on a single acquisition.
  • Waiting to see how German cannabis laws evolve before making a long-term commitment.

With Germany’s regulatory environment in flux, High Tide is playing it safe. But if the market stabilizes, expect the company to make another move soon.

FacebookTwitterPinterestLinkedInTumblrRedditVKWhatsAppEmail

Lars Beckers

Lars Beckers is a distinguished senior content writer at MMJ Gazette, bringing a wealth of experience and expertise to the realm of medical marijuana and cannabis-related content. With a deep understanding of the industry and a passion for sharing knowledge, Lars's articles offer readers comprehensive insights and engaging narratives in the dynamic world of cannabis. Known for his meticulous research, clarity of expression, and commitment to delivering high-quality content, Lars brings a seasoned perspective to his work, educating and informing audiences on the latest trends and developments in the field.

Illinois and Maine Weigh Marijuana Consumption Rules for Venues and Events
MediPharm to Sell British Columbia Cannabis Facility to Rubicon for $4.5M
Related posts
  • Related posts
  • More from author
Marijuana

Colorado THC Vapes Flooded with Converted Hemp, Experts Sound Alarm

January 31, 20260
Cannabis

California Smashes Own Record: $609 Million in Illegal Cannabis Destroyed

January 29, 20260
Marijuana

Trump Allies Push to Kill Arizona Adult-Use Marijuana Sales

January 28, 20260
Load more
Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH
PROMOTIONS
RECENT POSTS
  • Colorado THC Vapes Flooded with Converted Hemp, Experts Sound Alarm
  • California Smashes Own Record: $609 Million in Illegal Cannabis Destroyed
  • Trump Allies Push to Kill Arizona Adult-Use Marijuana Sales
  • Florida’s Marijuana Legalization Battle Hits New Lows in 2026
  • Montana Cannabis Sales Smash Records with $327 Million Haul
  • Cannabis M&A Surge Sparks Hope After Trump Order
  • Massachusetts Cannabis Ban Hit by Fraud Claims in 2026 Vote
  • Texas Medical Cannabis Set to Explode in 2026
  • Cannabis Firms Face HR Compliance Crunch in 2026
  • Oregon Cannabis Sales Drop in 2025 Despite Record Harvests
    © MMJ Gazette. 2024
    • About
    • Contact Us
    • Privacy Policy
    • Terms and Conditions
    • Authors